This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Diving into the GEMINI-2 Phase 3 clinical trial data on imsidolimab in patients with GPP.
Ticker(s): ANABWho's the expert?
Institution: Travis Partners
- Board certified dermatologist specializing in inflammatory dermatoses.
- Currently manages 550 patients with atopic dermatitis.
- Familiar with the recent announcement from Lilly regarding Lebrikizumab monthly maintenance dosing maintained durable skin clearance in their Phase 3 Monotherapy Atopic Dermatitis Trials.
Interview Goalto discuss the current standard of care and the potential of imsidolimab, an IgG4 antibody being developed by AnaptysBio for the treatment GPP.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
